Q-omics provides the consensus-scored MTND2P28 profile across patient tissues and cancer cell-line models. MTND2P28 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MTND2P28 is differentially expressed in 10, with the highest sampling consensus in KIRP. Additionally, MTND2P28 RNA expression shows 17,299 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, KIRP, and UVM as cancer lineages where MTND2P28 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTND2P28 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTND2P28 survival associations across molecular data types. MTND2P28 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTND2P28 RNA expression–survival associations across cancer types. High MTND2P28 expression shows unfavorable associations in ESCA, MESO and STAD, but favorable associations in ACC, LUSC and KIRP. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify ACC as the clearest survival context for MTND2P28 RNA expression.
This table summarizes MTND2P28 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MTND2P28. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTND2P28 shows lower tumor expression in KIRP, BRCA, LUAD, KIRC and LIHC and higher tumor expression in KICH. The KIRP box plot shows higher MTND2P28 RNA expression in normal versus tumor tissue (log2 FC = −1.694, t-test p = .004).
This table shows molecular features associated with MTND2P28 in patient tissues and cancer cell lines. In patient samples, MTND2P28 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
